Combination of conventional chemotherapeutics with …mct.aacrjournals.org/content/molcanther/early/2014/05/13/1535-7163... · Combination of conventional chemotherapeutics with redox-active
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Combination of conventional chemotherapeutics with redox-active cerium oxide nanoparticles – a novel aspect in cancer therapy
1Institute of Biochemistry & Molecular Biology I, Medical Faculty, Heinrich-Heine-University, 40225 Duesseldorf, Germany
2Advanced Materials Processing and Analysis Center, Nanoscience and Technology Center (NSTC), Mechanical, Materials Aerospace Engineering (MMAE), University of Central Florida, Orlando, Florida
3These authors contributed equally to this work.
Running title: Redox-active cerium oxide nanoparticles in cancer therapy
Financial support: S. Seal acknowledges the National Science Foundation (NSF) to partially fund the nanotechnology research under NSF NIRT (CBET-0708172) and NSF (CBET-0930170)
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
outcome and a higher benefit for patients, by enhancing anti-tumor activity and
lowering the damaging side effects of classical chemotherapeutics such as the model
substance Doxorubicin on healthy cells.
Acknowledgements
This work is part of the master thesis of E. K. at the Heinrich-Heine-University of
Düsseldorf. We thank C. Wyrich for excellent technical assistance. S. Seal
acknowledges the National Science Foundation (NSF) to partially fund the
nanotechnology research under NSF NIRT (CBET-0708172) and NSF (CBET-
0930170). We would like to thank Kate S. Carroll for providing the α-hapten antibody.
References
1. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine : nanotechnology, biology, and medicine 2007;3:20-31. 2. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology 2007;2:751-60. 3. Florence AT. "Targeting" nanoparticles: The constraints of physical laws and physical barriers. Journal of controlled release : official journal of the Controlled Release Society 2012. 4. Jain KK. Advances in the field of nanooncology. BMC medicine 2010;8:83. 5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians 2012;62:10-29. 6. Garbe C, Leiter U. Melanoma epidemiology and trends. Clinics in dermatology 2009;27:3-9.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
7. Lin W, Huang YW, Zhou XD, Ma Y. Toxicity of cerium oxide nanoparticles in human lung cancer cells. International journal of toxicology 2006;25:451-7. 8. Eom HJ, Choi J. Oxidative stress of CeO2 nanoparticles via p38-Nrf-2 signaling pathway in human bronchial epithelial cell, Beas-2B. Toxicology letters 2009;187:77-83. 9. Perez JM, Asati A, Nath S, Kaittanis C. Synthesis of biocompatible dextran-coated nanoceria with pH-dependent antioxidant properties. Small 2008;4:552-6. 10. Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nature nanotechnology 2006;1:142-50. 11. Tarnuzzer RW, Colon J, Patil S, Seal S. Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage. Nano letters 2005;5:2573-7. 12. Alili L, Sack M, Karakoti AS, Teuber S, Puschmann K, Hirst SM, et al. Combined cytotoxic and anti-invasive properties of redox-active nanoparticles in tumor-stroma interactions. Biomaterials 2011;32:2918-29. 13. Alili L, Sack M, von Montfort C, Giri S, Das S, Carroll KS, et al. Downregulation of Tumor Growth and Invasion by Redox-Active Nanoparticles. Antioxidants & redox signaling 2013. 14. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature reviews Cancer 2008;8:705-13. 15. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature reviews Cancer 2004;4:891-9. 16. Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK. Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 2010;46:1159-69. 17. Lechner D, Weltermann A. [Pathophysiology of chemotherapy-associated thrombosis]. Hamostaseologie 2009;29:112-20. 18. Perrino C, Schiattarella GG, Magliulo F, Ilardi F, Carotenuto G, Gargiulo G, et al. Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management. Current vascular pharmacology 2012. 19. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological reviews 2004;56:185-229. 20. Du C, Deng D, Shan L, Wan S, Cao J, Tian J, et al. A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery. Biomaterials 2013;34:3087-97. 21. Seo YH, Carroll KS. Profiling protein thiol oxidation in tumor cells using sulfenic acid-specific antibodies. Proceedings of the National Academy of Sciences of the United States of America 2009;106:16163-8. 22. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. Journal of the National Cancer Institute 1973;51:1417-23. 23. Bayreuther K, Francz PI, Gogol J, Kontermann K. Terminal differentiation, aging, apoptosis, and spontaneous transformation in fibroblast stem cell systems in vivo and in vitro. Annals of the New York Academy of Sciences 1992;663:167-79. 24. Stuhlmann D, Ale-Agha N, Reinehr R, Steinbrenner H, Ramos MC, Sies H, et al. Modulation of homologous gap junctional intercellular communication of human dermal fibroblasts via a paracrine factor(s) generated by squamous tumor cells. Carcinogenesis 2003;24:1737-48. 25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of immunological methods 1983;65:55-63. 26. Karakoti AS, Kuchibhatla SVNT, Babu KS, Seal S. Direct synthesis of nanoceria in aqueous polyhydroxyl solutions. J Phys Chem C 2007;111:17232-40. 27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5. 28. Modifications of Alkaline Microgel Electrophoresis for Sensitive Detection of DNA Damage. International journal of radiation biology 1994;66:23-8.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
29. Albrecht C, Borm PJ, Unfried K. Signal transduction pathways relevant for neoplastic effects of fibrous and non-fibrous particles. Mutation research 2004;553:23-35. 30. Woodward WA, Strom EA, McNeese MD, Perkins GH, Outlaw EL, Hortobagyi GN, et al. Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. International journal of radiation oncology, biology, physics 2003;57:327-35. 31. Park EJ, Choi J, Park YK, Park K. Oxidative stress induced by cerium oxide nanoparticles in cultured BEAS-2B cells. Toxicology 2008;245:90-100. 32. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clinica chimica acta; international journal of clinical chemistry 2003;329:23-38. 33. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases. Trends in molecular medicine 2003;9:169-76. 34. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000;21:361-70. 35. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine : nanotechnology, biology, and medicine 2008;4:273-82. 36. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14:1310-6. 37. Heckert EG, Karakoti AS, Seal S, Self WT. The role of cerium redox state in the SOD mimetic activity of nanoceria. Biomaterials 2008;29:2705-9. 38. Smylie MG, Wong R, Mihalcioiu C, Lee C, Pouliot JF. A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Investigational new drugs 2007;25:155-9. 39. Mishina NM, Tyurin-Kuzmin PA, Markvicheva KN, Vorotnikov AV, Tkachuk VA, Laketa V, et al. Does cellular hydrogen peroxide diffuse or act locally? Antioxidants & redox signaling 2011;14:1-7. 40. De Marzi L, Monaco A, De Lapuente J, Ramos D, Borras M, Di Gioacchino M, et al. Cytotoxicity and genotoxicity of ceria nanoparticles on different cell lines in vitro. International journal of molecular sciences 2013;14:3065-77.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950
Published OnlineFirst May 13, 2014.Mol Cancer Ther Maren Sack, Lirija Alili, Elif Karaman, et al. cancer therapyredox-active cerium oxide nanoparticles - a novel aspect in Combination of conventional chemotherapeutics with
Updated version
10.1158/1535-7163.MCT-13-0950doi:
Access the most recent version of this article at:
Manuscript
Authoredited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 13, 2014; DOI: 10.1158/1535-7163.MCT-13-0950